keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonate

keyword
https://www.readbyqxmd.com/read/29146440/clodronate-a-vesicular-atp-release-blocker
#1
REVIEW
Yoshinori Moriyama, Masatoshi Nomura
Clodronate is a first-generation bisphosphonate used worldwide for antiresorptive therapy for osteoporosis. Although clodronate is analgesic in nature, its mechanism and efficacy were unknown for some time. Recently, clodronate was identified as a selective and potent inhibitor for vesicular nucleotide transporter (VNUT), a transporter responsible for vesicular storage of ATP. Clodronate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain following blockade of purinergic chemical transmission...
November 13, 2017: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/29146093/treatment-status-and-radiographic-features-of-patients-with-atypical-femoral-fractures
#2
Hiroshi Hagino, Naoto Endo, Tetsuji Yamamoto, Atsushi Harada, Jun Iwamoto, Naoki Kondo, Tasuku Mashiba, Satoshi Mori, Junichi Nakamura, Seiji Ohtori, Akinori Sakai, Junichi Takada, Yoshiharu Kato
BACKGROUND: The Japanese Orthopaedic Association (JOA) has been surveying approximately 3000 orthopedic surgery hospitals and clinics with inpatient facilities nationwide to collect information on atypical femoral fractures (AFFs) and patient characteristics since 2010. The present study aims to examine radiographic images and clarify the relationship between radiographic and patient characteristics of patients with AFF and treatment status. METHODS: The study involved 1996 facilities certified as clinical training sites by the JOA and 912 clinics with inpatient facilities affiliated with the Japanese Clinical Orthopaedic Association (JCOA)...
November 13, 2017: Journal of Orthopaedic Science: Official Journal of the Japanese Orthopaedic Association
https://www.readbyqxmd.com/read/29144808/osteoporotic-fractures-during-bisphosphonate-drug-holiday-fractures-bisphosphonate-drug-holidays
#3
Brittany Bindon, William Adams, Neelam Balasubramanian, Jasmin Sandhu, Pauline Camacho
OBJECTIVE: Bisphosphonate (BP) drug holidays are recommended to lower the risk of rare adverse events, such as atypical femoral fractures and osteonecrosis of the jaw. However, there are minimal data on the optimal duration of these holidays. Our aim was to determine the clinical and laboratory parameters associated with increased fracture risk in patients on BP drug holiday. METHODS: A retrospective chart review was conducted of 401 patients with osteopenia or osteoporosis who began a BP drug holiday from 2004 to 2013...
November 16, 2017: Endocrine Practice
https://www.readbyqxmd.com/read/29143901/combined-vertebral-augmentation-and-radiofrequency-ablation-in-the-management-of-spinal-metastases-an-update
#4
REVIEW
Ning Mao Kam, Julian Maingard, Hong Kuan Kok, Dinesh Ranatunga, Duncan Brooks, William C Torreggiani, Peter L Munk, Michael J Lee, Ronil V Chandra, Hamed Asadi
Spinal metastases are the most commonly encountered tumour of the spine, occurring in up to 40% of patients with cancer. Each year, approximately 5% of cancer patients will develop spinal metastases. This number is expected to increase as the life expectancy of cancer patients increases. Patients with spinal metastases experience severe and frequently debilitating pain, which often decreases their remaining quality of life. With a median survival of less than 1 year, the goals of treatment in spinal metastases are reducing pain, improving or maintaining level of function and providing mechanical stability...
November 16, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29133976/bisphosphonates-atherosclerosis-and-vascular-calcification-update-and-systematic-review-of-clinical-studies
#5
REVIEW
Carla Caffarelli, Andrea Montagnani, Ranuccio Nuti, Stefano Gonnelli
Background: Epidemiologic and clinical data have suggested the existence of a biologic linkage between the bone system and the vascular system. Bisphosphonates (BPs) are effective inhibitors of bone resorption and are currently considered the drugs of choice for the prevention and treatment of osteoporosis and related fractures. Data from several publications have suggested that BPs may also be effective in reducing the atherosclerotic process and vascular calcification, but the results of these studies are contrasting...
2017: Clinical Interventions in Aging
https://www.readbyqxmd.com/read/29132335/topical-zoledronic-acid-decreases-micromotion-induced-bone-resorption-in-a-sheep-arthroplasty-model
#6
Thomas Jakobsen, Søren Kold, Juan Shiguetomi-Medina, Jorgen Baas, Kjeld Soballe, Ole Rahbek
BACKGROUND: Initial micromotion of a total hip replacement is associated with aseptic loosening. The use of bisphosphonates could be one way to reduce peri-implant bone resorption induced by micromotion. Bisphosphonates compounds are inhibitors of bone resorption. The aim of this study was to investigate whether local treatment with bisphosphonate would reduce bone resorption and fibrous tissue around an experimental implant subjected to micromotion. METHODS: One micromotion implant were inserted into each medial femoral condyle in ten sheep...
November 13, 2017: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/29130610/the-effects-of-icariin-on-wound-healing-of-extraction-sites-with-administration-of-zoledronic-and-dexamethasone-a-rat-model-study
#7
Jie Liu, Nikos Mattheos, Cheng Su, Chuanxi Deng, Nanyu Luo, Zekun Wang, Hua Tang
OBJECTIVE: This study was intended to investigate the effects of Icariin on the healing of tooth extraction sites under systemic administration of Zoledronic and Dexamethasone. METHOD: Thirty female rats underwent bilateral ovariectomy and were randomly assigned to 5 groups: SS group received weekly injection of saline while ZD, ZD+LICA, ZD+MICA and ZD+HICA groups received Zoledronic with Dexamethasone for 8 weeks. One week later, mandibular first molars were extracted in all groups...
November 11, 2017: Journal of Oral Pathology & Medicine
https://www.readbyqxmd.com/read/29129406/neuropeptide-y-y2-antagonist-treated-ovariectomized-mice-exhibit-greater-bone-mineral-density
#8
K L Seldeen, P G Halley, C H Volmar, M A Rodríguez, M Hernandez, M Pang, S K Carlsson, L J Suva, C Wahlestedt, B R Troen, S P Brothers
Osteoporosis, a disease characterized by progressive bone loss and increased risk of fracture, often results from menopausal loss of estrogen in women. Neuropeptide Y has been shown to negatively regulate bone formation, with amygdala specific deletion of the Y2 receptor resulting in increased bone mass in mice. In this study, ovariectomized (OVX) mice were injected once daily with JNJ-31020028, a brain penetrant Y2 receptor small molecule antagonist to determine the effects on bone formation. Antagonist treated mice had reduced weight and showed increased whole-body bone mineral density compared to vehicle-injected mice...
November 7, 2017: Neuropeptides
https://www.readbyqxmd.com/read/29127574/biologic-treatment-for-chronic-recurrent-multifocal-osteomyelitis-report-of-four-cases-and-review-of-the-literature
#9
REVIEW
Elena Tronconi, Angela Miniaci, Michelangelo Baldazzi, Laura Greco, Andrea Pession
Chronic recurrent multifocal osteomyelitis (CRMO) is a rare non-infectious inflammatory disorder with unpredictable clinical course, characterized by acute exacerbations and spontaneous remissions. There are no randomized-controlled trials about treatment options. Non-steroidal anti-inflammatory drugs (NSAID) are the first-line treatment option; glucocorticoids seem to be effective; positive outcomes have been obtained with bisphosphonates. In the last few years successful use of biologic agents like anti-TNF agents has been reported...
November 11, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29125079/-relapse-of-chronic-inflammatory-demyelinating-polyneuropathy-following-treatment-with-zoledronic-acid
#10
M Loef, E C T Geijteman, K J Beelen, M Bornebroek, D H Schweitzer
BACKGROUND: Zoledronic acid is a nitrogen-containing bisphosphonate that is frequently used in the treatment of osteoporosis. Many patients experience a so-called acute-phase reaction during initial treatment; this is characterized by flu-like symptoms and fever. CASE DESCRIPTION: We describe a 61-year-old woman who suffered from chronic inflammatory demyelinating polyneuropathy (CIDP), and who was started on intravenous zoledronic acid treatment as adjuvant therapy for breast cancer...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29124881/the-implications-of-baseline-bone-health-assessment-at-initiation-of-androgen-deprivation-therapy-for-prostate-cancer
#11
Peter S Kirk, Tudor Borza, Vahakn B Shahinian, Megan E V Caram, Danil V Makarov, Jeremy B Shelton, John T Leppert, Ryan M Blake, Jennifer A Davis, Brent K Hollenbeck, Anne Sales, Ted A Skolarus
OBJECTIVES: To assess bone density testing (BDT) use among prostate cancer survivors receiving ADT, and downstream implications for osteoporosis and fracture diagnoses as well as pharmacologic osteoporosis treatment in a national integrated delivery system. METHODS: We identified 17,017 men with prostate cancer who received any ADT between 2005 and 2014 using Veterans Health Administration cancer registry and administrative data. We identified claims for BDT within a 3-year period of ADT initiation...
November 10, 2017: BJU International
https://www.readbyqxmd.com/read/29121889/prevalence-and-associated-factors-of-medication-non-adherence-in-hematological-oncological-patients-in-their-home-situation
#12
Linda Bouwman, Corien M Eeltink, Otto Visser, Jeroen J W M Janssen, Jolanda M Maaskant
BACKGROUND: Medication non-adherence is associated with poor health outcomes and increased health care costs. Depending on definitions, reported non-adherence rates in cancer patients ranges between 16 and 100%, which illustrates a serious problem. In malignancy, non-adherence reduces chances of achievement of treatment response and may thereby lead to progression or even relapse. Except for Chronic Myeloid Leukemia (CML), the extent of non-adherence has not been investigated in hematological-oncological patients in an outpatient setting...
November 9, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29118758/combining-v%C3%AE-9v%C3%AE-2-t-cells-with-a-lipophilic-bisphosphonate-efficiently-kills-activated-hepatic-stellate-cells
#13
Xiaoying Zhou, Yanzheng Gu, Hongying Xiao, Ning Kang, Yonghua Xie, Guangbo Zhang, Yan Shi, Xiaoyu Hu, Eric Oldfield, Xueguang Zhang, Yonghui Zhang
Activated hepatic stellate cells (aHSCs) are now established as a central driver of fibrosis in human liver injury. In the presence of chronic or repeated injury, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) can occur, so there is interest in down-regulating aHSCs activity in order to treat these diseases. Here, we report that Vγ9Vδ2 T cells are reduced in patients with liver cirrhosis, stimulating us to investigate possible interactions between Vγ9Vδ2 T cells and aHSCs. We find that Vγ9Vδ2 T cells kill aHSCs and killing is enhanced when aHSCs are pretreated with BPH-1236, a lipophilic analog of the bone resorption drug zoledronate...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29112802/consensus-treatment-plans-for-chronic-nonbacterial-osteomyelitis-refractory-to-nonsteroidal-anti-inflammatory-drugs-and-or-with-active-spinal-lesions
#14
Yongdong Zhao, Eveline Y Wu, Melissa S Oliver, Ashley M Cooper, Matthew L Basiaga, Sheetal S Vora, Tzielan C Lee, Emily Fox, Gil Amarilyo, Sara M Stern, Jeffrey A Dvergsten, Kathleen A Haines, Kelly A Rouster-Stevens, Karen B Onel, Julie Cherian, Jonathan S Hausmann, Paivi Miettunen, Tania Cellucci, Farzana Nuruzzaman, Angela Taneja, Karyl S Barron, Matthew C Hollander, Sivia K Lapidus, Suzanne C Li, Seza Ozen, Hermann Girschick, Ronald M Laxer, Fatma Dedeoglu, Christian M Hedrich, Polly J Ferguson
OBJECTIVE: To develop standardized treatment regimens for chronic nonbacterial osteomyelitis (CNO), also known as chronic recurrent multifocal osteomyelitis (CRMO) to enable comparative effectiveness treatment studies. METHODS: Virtual and face-to-face discussions and meetings were held within the CNO subgroup of the Childhood Arthritis and Rheumatology Research Alliance (CARRA). A literature search was conducted, and CARRA membership was surveyed to evaluate available treatment data and identify current treatment practices...
November 7, 2017: Arthritis Care & Research
https://www.readbyqxmd.com/read/29112505/effects-of-bisphosphonates-on-orthodontic-treatment-and-the-tmj-a-systematic-review
#15
Bhumija Gupta, Shilpa Singh, Ross H Tallents, Emile Rossouw
No abstract text is available yet for this article.
August 2017: Journal of Clinical Orthodontics: JCO
https://www.readbyqxmd.com/read/29111914/incidence-of-osteonecrosis-of-the-jaw-onj-in-cancer-patients-with-bone-metastases-treated-with-bisphosphonates-and-or-denosumab-some-comments-and-questions
#16
Vittorio Fusco, Maura Rossi, Iolanda De Martino, Manuela Alessio, Antonella Fasciolo, Gianmauro Numico
No abstract text is available yet for this article.
November 7, 2017: Acta Clinica Belgica
https://www.readbyqxmd.com/read/29110061/the-impact-of-gi-events-on-persistence-and-adherence-to-osteoporosis-treatment-3-6-and-12-month-findings-in-the-music-os-study
#17
A Modi, S Sen, J D Adachi, S Adami, B Cortet, A L Cooper, P Geusens, D Mellström, J P Weaver, J P van den Bergh, P Keown, S Sajjan
The goal of this multinational, prospective, observational study was to examine the relationship between gastrointestinal (GI) events and self-reported levels of medication adherence and persistence in postmenopausal women. A total of 73.9% of patients remained on their osteoporosis (OP) therapy at month 12, although the presence of a GI event at baseline, month 3, and month 6 significantly reduced month 12 persistence among new users. The odds of a month-12 ADEOS score ≥ 20 were significantly lower among patients who experienced a GI event between baseline and month 6...
November 6, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/29109842/submental-perforator-flap-for-soft-tissue-reconstruction-in-bisphosphonate-related-osteonecrosis-of-the-jaws
#18
Jose-Antonio García-de Marcos, Juan Rey-Biel
Bisphosphonate-related osteonecrosis of the jaws (BRONJ) has emerged as an important and increasingly common comorbidity, especially in patients undergoing long-term treatment with high doses of bisphosphonates. The management of BRONJ remains controversial. Surgical treatment is necessary in severe cases. Treatment of the bone requires sequestrectomy or resection. Given the lack of sufficient mucosa to perform the operation and fragility of margins in many patients, local flaps are crucial. We report two cases of stage-3 BRONJ presenting secondary infection with Actinomyces , receiving treatment consisting of marginal resection of the necrotic bone, reinforcement with a reconstruction plate, and reconstruction of soft tissues using a submental perforator artery flap ipsilateral to the lesion...
December 2017: Craniomaxillofacial Trauma & Reconstruction
https://www.readbyqxmd.com/read/29105349/cost-effectiveness-of-bisphosphonates-for-prevention-of-fracture-related-to-glucocorticoid-induced-osteoporosis-in-malaysia
#19
Nurul-Ain Mohd-Tahir, Paraidathathu Thomas, Mohd-Shahrir Mohamed-Said, Mohd Makmor-Bakry, Shu-Chuen Li
INTRODUCTION: Glucocorticoid therapy is associated with an appreciable risk of bone loss leading to fractures that require expensive treatments. This study aimed to evaluate the cost-effectiveness of bisphosphonates for prevention of hip fracture in glucocorticoid-induced osteoporosis (GIOP) in Malaysia. METHOD: Retrospective data were collected from GIOP patients referred to the Universiti Kebangsaan Malaysia Medical Centre. Fracture events and direct medical costs were compared between bisphosphonates and calcium/vitamin D combination...
November 3, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29104057/high-payload-nanostructured-lipid-carriers-fabricated-with-alendronate-polyethyleneimine-ion-complexes
#20
Basma N Abd El-Hamid, Nitin K Swarnakar, Ghareb M Soliman, Mohamed A Attia, Giovanni M Pauletti
Oral bioavailability of the anti-osteoporotic drug alendronate (AL) is limited to ≤ 1% due to unfavorable physicochemical properties. To augment absorption across the gastrointestinal mucosa, an ion pair complex between AL and polyethyleneimine (PEI) was formed and incorporated into nanostructured lipid carriers (NLCs) using a modified solvent injection method. When compared to free AL, ion pairing with PEI increased drug encapsulation efficiency in NLCs from 10% to 87%. Drug release from NLCs measured in vitro using fasted state simulated intestinal fluid, pH 6...
November 8, 2017: International Journal of Pharmaceutics
keyword
keyword
49305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"